Life announced publication in the Journal of the American Medical Association, or JAMA, of a study that underscores the clinical utility of the company's early stage lung cancer test, Pervenio Lung RS. Launched in September, the genetic test has now been demonstrated to reliably identify patients who are at high risk for mortality following surgery even for the earliest stage of lung cancer. The test was initially validated through two independent, blinded retrospective studies involving approximately 1,500 patients, which were published in the March issue of The Lancet. The new study reports data from a subset of patients included in the larger validation studies. Specifically, it looks at those patients with "T1a, node-negative" tumors, cancers that are smaller than two centimeters in diameter and that have no detectable spread of the disease.